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ABSTRACT
Examining altered neural activation in patients with patellar tendinopathy: a preliminary study
Davi SM, Lepley LK, Lepley AS, Denegar CR, Aerni G, DiStefano LJ: Human Performance
Laboratory, Department of Kinesiology, University of Connecticut, Storrs, CT.

CONTEXT: Patellar tendinopathy (PT) is a common injury that can affect 15-45% of all
athletes, with nearly 50% of these athletes reporting no longer being able participate in sport due
to the severity of the injury. One of the consequences of PT leading to physical inactivity is
muscular weakness, particularly in the quadriceps, which may be attributed to arthrogenic
muscle inhibition (AMI). OBJECTIVE: To examine the extent of quadriceps AMI in
individuals suffering from PT and secondly, to compare subjective reports of pain and
dysfunction with objective measurements of PT diagnosis. DESIGN: Case-control. SETTING:
Laboratory PARTICIPANTS: Six participants with diagnosed PT (<80 on Victorian Institute of
Sport Assessment - Patella (VISA-p) and six healthy participants (VISA-p>80) matched to the
PT group based on age, mass, height, and gender. INTERVENTION: Each participant
completed one test session, which included patient-oriented outcome questionnaires, diagnostic
ultrasound (US), Hoffman’s Reflex (H-Reflex), superimposed burst to assess central activation
ratio (CAR), and a standardized jump landing test. Neuromuscular control during the jump
landing was evaluated using the Landing Error Scoring System (LESS) and electromyography
(EMG) of the vastus medialis and lateralis. MAIN OUTCOME MEASURES: H:M ratio,
CAR, LESS score, percent maximum muscle activation during CAR, and percent stance muscle
activation during the pre-loading and loading phases of jump landing were assessed between
groups using independent-t tests (α<0.05). RESULTS: With respect to CAR, the PT group
(95.13%±3.46) compared to the healthy group (98.54%±0.60) exhibited a significant loss of
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volitional muscle activation (P=.04). There were no differences between groups for H:M, LESS
score, or muscle activity (P>0.05). The PT group was then divided into two sub-groups:
Subjective (participants that were diagnosed with PT via subjective reports alone)(n=4) and
Objective (participants that were diagnosed via subjective reports and US)(n=2). The Objective
group demonstrated lower CAR, H-Reflex, muscle activity, and a higher LESS score than both
the Subjective PT group and the healthy group. CONCLUSION: This study was the first to
demonstrate deficits in the PT population using measures of peripheral sources of AMI. Further
research needs to be conducted on the extent of these deficits and whether AMI induced from PT
is associated with an increased risk of lower extremity injury.
Key Words: neuromuscular dysfunction, cortical alterations, peripheral inhibition
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Chapter I: Review of Literature
Patellar Tendinopathy
Knee injuries represent 15.2% of all high school injuries and can cause time losses for
athletes ranging from a few days to being career ending. 1 These injuries can include damage to
bone, ligament, cartilage, or tendon. Knee injuries are common in lower extremity sports with
patellar tendinopathy (PT) being one of the most prevalent. 1 While some knee injuries are more
severe their incidence rates are low compared to a knee injury like patellar tendinopathy, which
can affect up to 50% of athletes in at the elite volleyball level. 2 Patellar tendinopathy can have
long-term effects on the ability for athletes to continue with participation in sport. 3,4
Etiology and Prevalence
PT is very common and can occur in 15-45% of all athletes. 1,5-7 The prevalence of PT in
elite male volleyball players has been reported to be 45%. 2 PT does not only affect volleyball
athletes as prevalence in basketball can approach 30%. 6 The prevalence of PT can vary from
14.4% to 2.5% in non-elite athletes, with males being almost twice as likely than females to have
the condition. 5,7 Since PT is common in jumping sports at all levels of athletic participation, it is
important for clinicians to have an understanding of PT etiology.
The first step in understanding why PT so commonly affects jumping athletes is to
recognize what PT is and the role of the patellar tendon during activity. Tendinopathy is a
painful, chronic; overuse injury that is associated with degeneration and disorganization with no
evidence of inflammation within the tendon. 5,6 There are two main classifications of patellar
tendon injury; the first is inflammatory enthestis, which is described as inflammation at the site
where tendon intersects with bone and the second is tendinopathy. 8 Patellar tendinopathy
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typically presents as pain at the deep proximal portion of the tendon just inferior to the patella
that may or may not be accompanied by edema. 9 Patients may also present with pain during
knee extension exercises like squatting and jumping. Not only can PT produce pain but it has
been demonstrated to cause concentric quadriceps weakness in female fencers. 10 The main
purpose of tendon is to transfer force from a muscle to a bone thereby causing joint movement. 6
Other functions of tendon include energy storage and release in addition to protection of the
muscle from injury. 6 The patellar tendon must transmit a high volume of force form the
quadriceps to the tibia in a jumping sport.
Although the etiology of PT still is not completely understood, a few possible
explanations for this pathology have been suggested by the literature. PT is very common in
sports that include repetitive jumping and landing like basketball and volleyball. 5 Since tendon
tissue transfers force between muscle and bone, the PT is responsible for absorbing high loads
and converting this energy to mechanical work that can be utilized during dynamic activities,
such as jumping. Given the unique role of the tendon during high-loading activities, a high
volume of repetitive jumping is a risk factor. 6,9,11-15 Some other possible causes of PT include a
stiff landing technique, high jump performance, large waist girth, male gender, and high training
volume. 5 Each of these factors point towards tendinopathy developing when greater strain is
present. Jumping higher and having a large waist girth are two traits most often attributed to
males and may play a role in the high gender incidence rates. 5 The premise behind these two
ideas are that landing from a higher height and increased weight will cause more eccentric strain
during landing. Having a stiff landing technique is believed to cause increased tendon strain
because less energy is absorbed through supportive musculature that utilizes a limited range of
motion, thus transferring more force to the tendon. 5 A new perspective on PT in volleyball may
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come in the form of genetics, where researchers have found that volleyball players who are
carriers of the BMP4 and FGF3 genes may be predisposed to developing PT. 2
The prognosis for untreated PT is poor. Gisslen et al. 16 showed through a three-year
observation that patellar tendon condition did not change if training intensity remained the same.
The study followed 22 high school volleyball players, 11 males and 11 females, through three
years of school. Each player had both of his or her patellar tendons examined by ultrasound
(US), and power doppler (PD For participants who had clinically and sonographically diagnosed
PT,symptoms remain as long as intense training or competition was present. The results of this
study show that without rest PT will be a persistent problem for the jumping athlete.
In another study that included a measurement for the duration of PT, van der Worp et al.
17

found that the median length of time a patient suffered from PT was 24 months, however

duration of symptoms ranged from 1-219 months. Participants in the study were invited via
email to fill out an online questionnaire regarding their demographics, current knee injury status,
sport participation, and occupation. PT was assessed using the VISA-P. Men were twice as
likely to have PT, and those with a physically demanding job in addition to playing sports
regularly were at greater risk for developing PT. When untreated PT lasted an average of 24
months. Both of these studies demonstrate that untreated PT does not resolve without treatment
and a decrease in sport or work intensity. For the clinician, these studies help to outline why PT
should be taken seriously, especially in males that participate in sport at a high intensity.
Bisseling et al. 18 further illustrated how landing mechanics can both influence and be
influenced by PT. This study assigned 89 male participants into one of three experimental
groups; 1) a control group with no previous or current PT, 2) a group with a history of PT but no
current symptoms, and 3) a group that had PT at the time of the trials. Participants were asked to
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step off of boxes that were 30cm, 50cm, and 70cm high five times per box height landing one
foot on a force plate. The results of the study showed that the group with recent PT tended to
avoid patellar tendon loading during landing through lowering the velocity and rate of range of
motion chance of the ankle and knee, while participants with a history of PT tended to land much
more stiffly than their counterparts. These data not only suggest that PT can influence the
alteration of landing mechanics in the short term but that a stiff landing could either be a
potential cause of PT or a long term side effect of the disorder.
Signs and Symptoms
The signs and symptoms of PT are considerably better recognized and understood than
the etiology. One of the more common symptoms is pain over the proximal tendon during
loading activities like jumping and squatting. 6 A second indicator is pain on palpation of the
proximal tendon as it attaches to the inferior patella. 19 Although not as easy to assess clinically, a
study of patients with PT by Souza et al. 20 found that they display greater hip extensor activation
and decreased knee extensor activation when compared to asymptomatic controls during a
hopping task. The experiment compared seven men with history of PT to an equal control group
without history of PT. All participants were evaluated for their kinematics and kinetics and
asked to hop in place for 20 successful hops on a force plate. Even though the PT group did not
report painful hopping, they demonstrated a higher ratio of hip joint to knee joint effort than did
the control group. This study suggests that those suffering from PT will attempt to reduce knee
joint loading by using hip extensors to absorb landing forces, which shifts loading from the knee
to the hip. This shift in loading could possibly be due to a weakness, neuromuscular dysfunction
of the quadriceps muscle, or as a conscious effort to decrease pain.
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Signs and symptoms are important when making the determination of whether a patient is
suffering from PT, however the use of imaging devices is necessary in determining the extent of
tendon degeneration, disorganization, and vascularization. Magnetic resonance imaging (MRI),
ultrasound (US), and power doppler (PD) are all imaging tools used in the diagnosis of PT. 6 All
three instruments are non-invasive but US is the most widely used imaging for PT. US can be
used to show tendon thickness, structural changes, and neovascularization. 21 In addition, US has
a higher spatial resolution than MRI, resulting in a more detailed picture from a portable and
affordable unit. 21 Finally, although US has a similar specificity to MRI (.82) US has a higher
sensitivity (.87) than MRI (.57). 8 However, the US is not perfect and one of its biggest
drawbacks is that sonographic tendon abnormalities often appear in the absence of clinical
symptoms of PT, 22,23 as 10%-18% of tendons that are abnormal on US never become painful. 22
Some common abnormalities detected via US are tendon thickening, hypoechoicity of the
tendon, increased collagen bundle disorganization at the proximal tendon, and greater cross
sectional area. 22,24,25 While US is useful for visualizing structural abnormalities, both power and
color doppler are useful in determining vascularity within a tendon and have been able to show
an association between pain during activity and the amount of vascularization in the tendon. 16
This association is most likely due to an increase in pain causing chemotaxic factors being
carried to the injured area. One drawback of doppler is that only high flow rates, like those
sometimes present in PT, can be detected. 16 The MRI is the least used of the three because of
high costs and inability for differentiation between inflammation and degeneration in the
tendon.24
The Victorian Institute of Sport Assessment Scale – Patella (VISA-P) is a patient
reported outcomes questionnaire designed for individuals suffering from PT and is the most
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widely used assessment for PT. 26 The form consists of eight items that are split into two
sections. The first section consists of six parts that look to identify pain levels during activities
of daily living and functional tests, while the second section has two parts that target the patient’s
sport participation level. 26 The questionnaire is scored on a scale of 0-100 with 100 being a
patient that exhibits no signs or symptoms of PT and zero being the bottom of the scale, which is
the equivalent of total disability. A recent study 26 has shown that this scale is able to detect and
represent changes in the patient’s condition. What this means for the clinician is that he or she
will have an accurate idea of how their patient is or is not responding to treatment. The VISA-P
has also been shown to be accurate in both the online and written formats. It should be noted that
the questionnaire was not designed to be used in research with control subjects that are not
suffering from PT, and using the questionnaire in such a way could alter its results. 27
Arthrogenic Muscle Inhibition
Arthrogenic muscle inhibition (AMI) is often referred to as an ongoing reflex response to
joint injury that affects the periarticular musculature. 28,29 AMI is hypothesized to be the body’s
mechanism to protect the injured joint and prevent further painful stimuli. 30 AMI is caused by a
variety of peripheral and central mechanisms that result in either the loss of the ability to
volitionally activate alpha motor neurons or a decrease in the alpha motor neuron’s firing rate. 29
This decreases the ability of periarticular muscle to voluntarily and reflexively contract, which
can lead to atrophy and poor functional ability. 30 AMI has been detected in the musculature
surrounding the knee joint following injury, primarily in the quadriceps muscle group. 28,31
Interestingly it has been reported that anterior knee pain seems to cause a greater magnitude of
inhibition than does ligamentous injury. 32
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Peripheral Mechanisms
The neurologic pathways involved in AMI are complex, which is one of the key reasons
they are still not completely understood. However, AMI is thought to occur due to peripheral and
central inhibition or a combination of the two. In the peripheral pathway either effusion,
mechanoreceptor damage, and/or pain can cause altered afferent signaling from what would be
considered normal. For example, increased afferent activity is what takes place when a joint
becomes effused. 31 The effusion within the joint space causes a rise in group II articular afferents
discharge from the joint capsule due to the excessive fluid built up and activated
mechanoreceptors of the joint capsule. An example of altered afferent activity would be in the
case of destroyed mechanoreceptors from the loss of a ligament. 31 Normally, joint
mechanoreceptors relay information to periarticular musculature, but once they become damaged
the mechanoreceptors can no longer complete this function. Both increased and deceased
afferent signaling can cause presynaptic inhibition of the musculature surrounding the joint. In
the patellar tendinopathy population it is most likely that pain at the site of injury would cause
peripheral AMI due to altered afferent signaling of 1a fibers.
Central Mechanisms
Central mechanisms of AMI include pre-synaptic, cortical, and spinal mechanisms. At
the pre-synaptic level inhibitory interneurons release GABA, which decreases the ability of the
neuron to generate an action potential by causing chlorine to change the electrical gradient
surrounding the neuron. The change in this gradient reduces the amount of calcium entering the
pre-synaptic terminal and inhibits proper muscular activity. 30 To examine a second mechanism
of centrally originating AMI, Lepley et al. 33 demonstrated joint injury can cause alterations in
cortical excitability, which can act to modulate efferent signaling at the alpha motor neuron level.
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Rio et al 34 conducted similar work in which it was found that chronic PT can influence cortical
changes also.
AMI caused by the spinal pathway can originate from gamma motor neuron loop
dysfunction, reciprocal inhibition of type 1a afferent fibers, non-reciprocal inhibition of type 1b
fibers, and recurrent inhibition via Renshaw cells 35. In the gamma loop afferent signals from
within the injured joint are transmitted to gamma motor neurons (GMN). These afferent signals
into the GMN inhibit a signaling process between the GMN and intrafusal fibers within the
muscle spindle 34. This alters the shortening reaction of intrafusal fibers within the muscle
spindles and results in a decreased capacity for muscle contraction. 36 Along with the decrease in
contractibility, signals from 1a afferent to high threshold motor units are inhibited, which results
in decreased force output. 30 Inhibition of type 1a afferent fibers is caused by firing of motor
neurons in the agonist muscle group. This firing stops the antagonist group from working
correctly because both the agonist and antagonist groups cannot contract completely
simultaneously. Type 1b inhibition is caused by afferent signaling arising from the golgi tendon
organ to inhibit the agonist muscle group and activate the antagonist group. Renshaw cells work
in the spinal cord and cause inhibition of the target muscle group by decreasing the action
potential that is received by the alpha motor neuron. 30
Quantifying AMI
Whether to detect the presence of AMI or to quantify the amount of inhibition a muscle is
experiencing, researchers commonly utilize either the superimposed burst or interpolated twitch
technique. 37 One of the most often used equations to calculate muscle activation, which can be
used with either testing method, is the central activation ratio (CAR). The formula is derived for
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the patients maximum voluntary isometric contraction (MVIC) by their MVIC plus a stimulated
force measured in torque. 38

CAR = (MVIC) / (MVIC + stimulated force)

The force of contraction is measured on a dynamometer, which can quantify torque for
each MVIC. 37 The stimulated force described in the CAR equation is the amount of torque
caused by a superimposed electrical burst. This process will be described in detail later in this
paper. CAR is the percentage of complete muscle activation that is occurring. For example, a
patient demonstrating a CAR of 1.00 would mean that he or she had complete voluntary muscle
activation, while a CAR of .8 would signify that the muscle was activated to 80% of its complete
potential. 39
CAR measurements are used to determine the amount of voluntary activation possible for
the specific muscle. Roberts at al. 37 determined possible confounding variables that can
influence quadriceps CAR. The included variables were patient positioning, verbal cueing from
the clinician, synergistic muscle activation, and antagonist co-contraction. The purpose of
measuring CAR is to determine the amount of activation in a specific muscle. It is important that
only one muscle, or muscle group, be targeted without the use of synergists Synergistic muscle
activity includes trunk and arm muscle contractions to stabilize the upper body. An example of
antagonist muscles are the hamstring group co-contracting when the quadriceps group is
activated. Avoiding hamstring group activation is important because these muscles decrease
quadriceps activation force. If the patient is properly positioned and verbally cued on isolating
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the quadriceps, then synergist and antagonist muscle activation can be avoided. The study went
on to show that less synergistic muscle involvement can decrease CAR.
The superimposed burst (SIB) method is used to obtain the CAR to determine the total
possible torque that all of the motor units for a specific muscle could create in an ideal situation.
A SIB delivers electrical impulses that are able to increase the total number of motor units being
recruited, which increases torque beyond a patient’s MVIC. 37. The SIB can be delivered to a
muscle in a single, doublet, or train series of pulses. 40 While each method can be used to
identifyAMI the pulse trains or burst methods have been found to be more sensitive to central
activation failure (CAF) than the single or double methods. 38 The SIB method has been shown to
reliably measure central activation of the quadriceps. 37 Even though the method is reliable there
can be up to a 5% measurement error with the SIB technique. 41 There are different methods
demonstrated for performing SIB and two have been utilized for the quadriceps. The
possibilities include the vastus and rectus configurations and these can be set up with either selfadhesive or carbon impregnated electrodes. Both configurations and electrode types have been
shown to be interchangeable, which demonstrates the versatility of the SIB method. 42 One final
measure of versatility for the SIB method is that it can be used in the percent activation equation
with success rates similar to that of CAR. Researchers have been able to demonstrate that when
SIB is used with a doublet pulse configuration the percent activation equation correlate well to
CAR using SIB with a train of pulses. 40
Although the use of a superimposed burst technique to calculate CAR is effective at
quantifying AMI, one if the drawbacks is that the method cannot determine where AMI is being
generated from. The Hoffmann Reflex (H-Reflex) is a peripheral nerve stimulation technique
that has been used as an accessory to CAR because of the ability to assess the role that the
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spinal-reflex loop may play in the development of AMI. 43 An H-Reflex in a peripheral nerve is
an electrically induced equivalent to the muscular stretch reflex, and looks to account for levels
of inhibition discussed earlier (presynaptic, postsynaptic). To record H-Reflex an electrical
stimulation is delivered to a peripheral nerve, which causes an afferent signal discharge of the 1a
nerve fiber to the spinal cord, and the efferent “reflex” is detected using electromyography
(EMG) in muscles innervated by the stimulated nerve. 43 The resulting increase in electrical
activity within the muscle is represented as a wave on the computer and is considered to the “Hreflex”. In subjects with AMI a decrease in peak-to-peak amplitude of the “H-reflex” or an
increased stimulus voltage needed to elicit comparable peak-to-peak amplitude when compared
to a healthy or control limb and normalized to muscle response would denote an inability for the
1a afferent nerve to effectively transmit electrical impulses to the alpha motor neuron, resulting
in an inability to reflexively contract the muscle.
Many confounding variables exist when eliciting the H-Reflex during testing, therefore
the process must be performed in a controlled environment. As stated above, presynaptic
inhibition of afferent sensory signaling can greatly affect the amplitude of the H-reflex. Changes
in light, sound, noise, or body position are just a few of disturbances that can cause presynaptic
inhibition. 43 This inhibition occurs because any external stimuli require afferent signaling to
reach the spinal cord, as does the H-reflex stimulus. Any additional stimuli can dilute the
experimental stimulus for eliciting the H-reflex, which will result in decreased peak-to-peak
amplitude as detected though EMG assessment. 44
In addition to the H-reflex, another variable called the M-Wave is also elicited during Hreflex testing. As the electrical stimulus is increased, the higher threshold efferent limb of the
stimulated nerve (i.e. the alpha motor neuron) is directly depolarized. Once the alpha motor
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neuron fibers are directly depolarized, the EMG can detect the electrical activity from this event,
the M-Wave. 43 Since the M-Wave represents direct depolarization of the alpha motor neuron
there is no influence from the spinal cord. Thus, the M-Wave represents the maximal capacity of
the alpha motor neuron excitability, while the H-reflex represents the ability of afferent stimulus
to evoke efferent spinal cord excitability. These two waves are represented as a ratio of the
maximum peak-to-peak H-reflex amplitude compared to the maximum peak-to-peak M-Wave
amplitude, H-reflex Max: M-Wave Max. The comparison of the waves allows researchers to begin
to make inferences about the source of AMI. A decreased peak-to-peak H-Wave amplitude with
no associated decrease in peak-to-peak M-Wave amplitude is believed to show that the spinal
cord, which is not involved with the M-Wave, is influencing efferent signaling to the muscle
being tested. Normalizing H-relfex to muscle response allows the researcher to determine if
alterations in the H-reflex are also present during muscle response.
Quadriceps AMI
Quadriceps AMI is a common consequence of a variety of knee injuries. In particular, it
has been estimated that quadriceps strength deficits in patients with ACL ruptures range between
8%-45%. Some injuries that have been linked to quadriceps AMI are primary ACL injuries,
anterior knee pain and osteoarthritis. 29,30,37 Previously discussed in less detail, ACL injuries
damage mechanoreceptors in the ligament itself, which can cause abnormal afferent information
to be sent to the CNS and PNS and result in muscle inhibition. 30 This leads to an inability of the
patient to properly control the quadriceps muscle, potentially leading to biomechanical
alterations during gait and athletic participation, which could be problematic for active
individuals. 37
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Quadriceps weakness can have major effects for not only the athletic population but also
the general population that suffers from AMI. The quadriceps act eccentrically during gait, and a
weakened muscle with decreased contractility could adversely affect the gait cycle. 32 Quadriceps
weakness can also cause decreased dynamic joint stability, which could lead to decreased
functional ability and eventually tibiofemoral osteoarthritis (OA). 31,39
Palmieri-Smith and Thomas 30 have described some of the changes which take place in
the knee joint when the ipsilateral quadriceps is experiencing weakness and how this may effect
articular cartilage. First, the load placed upon the knee joint increases as quadriceps strength
decreases. The authors believe this was due to the quadriceps acting as a shock absorber for the
knee. When the quadriceps muscles are weak they absorb less force, and more force is
transmitted to the knee joint and consequently the articular cartilage. Second, altered joint
kinematics due to muscular inhibition also lead to new stresses to the articular cartilage which
were not previously present. This increased stress on articular cartilage is a possible cause for
OA.
Manal and Snyder-Mackler 45 looked to identify quadriceps AMI that may be present
after patellar contusions. In 16 participants with patellar contusion, only 1/3 of patients
experienced quadriceps muscle AMI with the clinical diagnosis of AMI only being made by
determining %MVIC. Patient reported outcomes for those diagnosed with AMI did not show any
deficits in daily function. The results of this study show that AMI is possible with a relatively
benign injury, however, without the use of laboratory equipment AMI could easily go unnoticed.
Once AMI is detected, or thought to be detected, it must be quantified. Kuenze et al. 41
examined 22 participants with a history of ACL reconstruction in an attempt to determine return
to participation criteria for individuals with quadriceps AMI. The study found that 3.00Nm/Kg of
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normalized quadriceps strength was a good indicator of positive patient reported outcomes in
regards to knee function, as was CAR symmetry of greater than 99.2 %. These data provide
clinicians will a baseline for which to compare an individual suspected to be suffering from
AMI.
Although AMI has been linked to ACL and other major knee joint injuries, it has yet to
be shown as a result of PT. Some evidence does exist that PT can cause concentric quadriceps
weakness in female fencers. 10 Though concentric weakness could signal that AMI is present, it
alone is not a definitive sign. As in ACL injury, CAR and associated testing must be done to
determine if the muscular weakness is due to AMI and where this AMI may be originating from.
Movement Assessment
The Landing Error Scoring System (LESS) is a clinical movement assessment tool,
which was designed to help identify individuals at risk for ACL injury, but can also be used to
help assess neuromuscular control during functional movement. The LESS requires participants
to jump off of a 30cm high box onto a force plate set at 50% of the participant’s height from the
front of the box while being recorded by video cameras in the frontal and sagittal planes (Figure
1). 46 To complete the trial the patient must successfully perform the jump, landing, and second
jump three times (Figure 2).

Figure 2. 46
Figure 1. 46
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After the patient has been filmed a clinician reviews the videos and grades the
participant. There are 22 error types that the LESS grades that range from knee valgus at initial
contact to joint stiffness. 46 A high score on the LESS correlates to poor biomechanical landing
abilities. A poor score greater than 5 is considered predictive of ACL injury. 47 The LESS has
been shown to; 1) have good validity when compared to motion analysis, 2) have good interrater
(ICC2,k – 0.84 and SEM – 0.71) and intrarater (ICC2,1 – 0.91 and SEM – 0.42) reliability, and 3)
identify at risk individuals. 46,48 This makes the LESS a clinically applicable test in the fields of
overall lower extremity injury including ACL research, rehabilitation, and prevention strategies,
although the LESS has not been specifically studied in the PT population.
Future Directions
The purpose of this study is to identify AMI and the mechanisms leading to poor neural
control. If this study identifies altered neuromuscular outcomes future research will seek to
identify ways to target pathways that lead to AMI or poor neural control. One potential
treatment is cryotherapy, which is a common modality in the clinical setting that might have
further application in the treatment of AMI.
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A second possible clinical approach to treating

AMI is through motor neuron treatments, like neuromuscular electrical stimulation 35,49,50. This
is thought to work is by directly stimulating the affected motor neurons, causing a contraction to
occur in inhibited muscle fibers. 31 A third clinical approach to treating AMI is through
addressing the PT itself by using eccentrics to load the tendon 51-53
Conclusion
Patella tendinopthy is common, especially in athletes that participate in jumping sports.
In athletes with PT, the physical and mechanical properties of pathological tendon differ from
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normal. The changes in tendon properties, which are evident in PT, have been shown to
decrease concentric quadriceps strength. Decreases in quadriceps strength have also been
evaluated in participants with ACL injury and in those with OA. A component of the quadriceps
strength impairment in both of these conditions is related to diminished neuromuscular control.
Alterations in neuromuscular control after joint injury is often referred to as AMI. CAR is one of
the primary methods used to assess the magnitude of AMI but does not identify the pathways
underlying the deficit. To help identify exactly where the source of the AMI is originating from
other measures must be utilized. A combination of H-Reflex testing, to evaluate spinal cord
influence, EMG, to determine alterations in dynamic muscular activity, and LESS score, a
functional means of evaluating neuromuscular control were all used to make a complete picture
of why AMI is present. Quantifying the effects of quadriceps AMI induced by PT have not been
extensively investigated and has not been quantified in terms of non-functional, CAR and HReflex, and functional, EMG and LESS score, measures. Therefore, the purpose of this
investigation is to quantify AMI that is potentially present as a result of PT using the CAR, and
then to identify the pathways that are leading to the AMI using H-Relex, EMG, and LESS score.
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Chapter II: Introduction
Patellar tendinopathy (PT) is a degeneration of the patellar tendon that can impair athletic
performance, quality of life, and neuromuscular control that may lead to future injury. 1 PT is
particularly prevalent in jumping sports, such as volleyball, where it can affect close to 50% of
elite male athletes in the sport. 2 Untreated PT can become a source of painful physical activity
participation that can influence musculature around the knee by causing generalized weakness. 3
Consequently, nearly 33% of athletes that have chronic PT take longer than six months to return
to play. 4,5
Muscle weakness resulting from joint damage is often referred to as arthrogenic muscle
inhibition (AMI). 6,7 AMI is thought to be a mechanism of the body to protect a joint following
injury and is commonly seen in the quadriceps muscle group after anterior cruciate ligament
(ACL) injury. 8 Two pathways are known to influence AMI, central and peripheral, each varying
in ways of inhibiting muscle activity. 6-10 Peripherally induced AMI has been shown to be present
in both experimental and injury models in conjunction with persistent pain, which is possible in
patients with PT. 11 Losses in quadriceps strength and altered cortical excitability have been
documented in patients with PT, 3,12 but it is unknown if AMI might result from peripheral or
spinal mechanisms specifically in patients with PT.
AMI can be quantified in many ways, which includes measuring the central activation
ratio (CAR) and Hoffman’s reflex (H-Reflex). CAR identifies the presence of AMI, through
detecting a drop in volitional muscle activation that results from either a decrease in motor
neuron firing rate or the number of motor units being recruited 13, but cannot pinpoint the source
of the dysfunction (ie. either central or peripheral). While Hoffmann-Reflex (H-reflex) is the
normalization of spinal cord reflexivity to maximal muscle response (H:M ratio) in order to
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quantify peripherally originating AMI. H-Reflex is a method of stimulating 1a afferent fibers in
the muscle spindle and recording the electrical activity that occurs in the target muscle following
stimulation 9. Since the afferent fibers must travel through the spinal cord, any alteration in
resultant electrical activity from what is considered normal is attributed to spinal cord influence.
Electromyography (EMG) is used during testing of the H-Reflex to detect electrical
stimulus that is leaving the spinal cord or can be used to support other measures by showing how
a patient is engaging various muscles during physical activity. This is accomplished through
recording the electrical activity between two conduction points, commonly surface electrodes,
which takes place during depolarization while a muscle is at work. Alterations in the quality of
muscular activation may also influence movement control during functional activities. Certain
movements during sport-specific tasks, such as a jump landing, have been associated with lower
extremity musculoskeletal injury risk, and such, are important to understand. The Landing Error
Scoring System (LESS) was designed as a specific clinical movement assessment tool for the
jump-landing task. Together these measures allow for the quantification of AMI and the
identification of possible spinal cord involvement, along with the ability to understand muscular
activation throughout physical activity and the role this may play in altered mechanics during a
jump landing.
Thus, the purpose of this study was to evaluate the presence and origin of AMI in
individuals suffering from PT using CAR, EMG, and H-Reflex along with clinically applicable
measures, such as the LESS and subjective patient-oriented outcome scales. Our hypothesis is
that arthrogenic muscle inhibition will be present in patients with PT, leading to a decrease in
CAR, muscle activity, H:M ratio, and LESS score.
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Chapter III: Methods
Participants
12 males (n=6) and females (n=6) between the ages of 13-40, were recruited to
participate in this research study. Six participants were self-reported as having PT, with
symptomatic PT quantified as score of < 80 on the Victorian Institute of Sport Assessment Patella (VISA-P). Exclusionary criteria for PT participants were a history of lower extremity
surgery, any lower extremity injury in the previous six months (other than PT), or having a heart
related condition. Six other participants served as healthy controls, scoring between a 95 and 100
on the VISA-P. To be included in the control group, participants needed to be both healthy and
physically active at the time of the trial, with no previous history of lower extremity surgery,
current knee pain or have a heart related condition. Each participant in the PT group was gendermatched to a control participant that most closely resembled him or her in height and mass. All
participants completed informed consent forms, which were approved by the University of
Connecticut’s Institutional Review Board.
Quadriceps Activation Testing
To quantify defects in volitional muscle activation and determine whether AMI was
present, superimposed burst (SIB) testing 14 was performed on a Biodex dynamometer (System 4,
Biodex Medical Systems, Inc, Shirley, NY). 15 Each participant was positioned in the Biodex so
that his or her hips and knees were both flexed to 90 degrees and the torso was flexed to 90
degrees. 7 Two 7x13cm self adhesive stimulating electrodes were placed on the participant’s
thigh in space that had already been cleaned with isopropyl alcohol and was shaved free of hair.
The superior electrode was placed over the vastus lateralis so that its medial border was in line
with the anterior superior iliac spine at the level of the greater femoral trochanter. The inferior
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electrode was placed over the vastus medialis so that the lateral border aligned with the midpoint
of the patella at a height of 1.5 inches above the superior pole of the patella.
Once the participants were properly positioned, a series of three introductory practice trials
were conducted. For the practice trials the participants were instructed to extend their knee at 25,
50, and 75% of their perceived maximal exertion. At the same time as contraction, a stimulus of
corresponding percentage of the maximal 150 volts was delivered to the participant’s quadriceps.
A custom written program (LabVIEW Version 8.5; National Instruments Corporation, Austin,
TX) delivered each stimulus as a 100ms train of 10 stimuli, at 100 pps, with a pulse duration of
0.6ms, and a 0.01ms pulse delay 16. After the introductory practice trials were complete the
participant was instructed to complete three MVIC trials, or until the researcher determined that
the participant was putting forth full effort, without any electrical stimulation. Finally, three
MVIC trials were completed along with electrical stimulation equal to 100% of the 150 volt
maximum. The participants were given visual feedback and verbal encouragement during each
trial and a 60 second recovery session between each trial. The entire procedure was then
completed on the contralateral limb and the order of tested limbs was counterbalanced. The
lowest of the three trials was used in data analysis. A Grass S48 dual-output square-pulse
stimulator and SIU8T isolation unit (Grass-Telefactor, West Warwick, RI) was used in the
application of the superimposed bursts.
Additionally, to quantify alterations in muscle activity prior to the burst, surface
electromyographical electrodes (EMG, Desktop DTS, myoMuscle, Scottsdale AZ, USA) were
secured over the muscle bellies of the vastus lateralis and medialis according to the technique
described by Delagi et al. 17 and were sampled (1500Hz) and synchronized (Analog Input
System, Noraxon Inc. Scottsdale AZ, USA) with the torque from the dynamometer. EMG data
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data was collected from the onset of muscle contraction was defined at 7.5Nm 18 to assure that
baseline movement had been exceeded until 100 msec prior to the superimposed burst.
Hoffmann reflex testing
To measure difference in spinal-reflexive excitability H-Reflex testing 9 was performed
using an electromyography (EMG) and stimulation unit (STM100A, BIOPAC Systems, Inc.).
Participants were positioned supine on a portable treatment table with their arms placed at their
side, head resting in neutral on a pillow, and knees bent in about 10-15 degrees of flexion and
supported by a half bolster. Two 10mm, pre-gelled Ag-AgCl EMG electrodes (EL503, BIOPAC
Systems, Inc.) were placed 1.75 cm apart in cleaned and shaven sites over the medial vastus
medialis muscle belly. EMG signals were band-pass filtered from 10 to 50 Hz and collected at
1024HZ with a common-mode-rejection ratio of 110 dB. A 2mm shielded disc stimulating
electrode (EL2524S, BIOPAC Systems Inc) was positioned over the femoral nerve and secured
with hypoallergenic tape and a 7x13cm self adhesive electrode was positioned over the
hamstring and used as a dispersive electrode. A 1ms square wave stimulus was produced using
the BIOPAC stimulator module and a 200 volt maximum stimulus adaptor (STMISOC, BIOPAC
Systems Inc.) and was delivered to the femoral nerve.
The participants maintained constant head, eye, and hand position during testing by
focusing on a small circle on the ceiling. Once each participant was settled, the stimulus was
applied in 2 volt increments until a maximal H-Reflex was obtained. After the first maximal
reflex was obtained, three more were elicited using the same voltage setting. Next, the voltage
was increased until a maximal muscle response was obtained, and followed by three concurrent
trials of eliciting maximal muscle response. The average of the three maximal H-Reflexes were
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normalized to the average of the three maximal muscle responses for analysis. This procedure
was then repeated for the contralateral limb and the order of tested limbs was counterbalanced.
Sonographic Assessment
Sonographic measurements were taken using an ultrasound unit (Philips, 12-5L linear
transducer). Participants were supine with the knee flexed between 80-90 degrees in order to
relax the quadriceps muscles. 19 A clinician trained in the use of US for studying patellar tendon
abnormalities obtained both longitudinal and transverse images of the patellar tendon. The
abnormalities studied were tendon thickening, hypochoic regions, and areas of
neovascularization. Tendons with one or more abnormality were considered to be objectively
defined PT. Abnormality was used to break the PT group into two subgroups, where participants
with tendon abnormality were defined as objective PT and subjects without abnormality were
defined as subjective PT. These images were transferred to an external had drive so that could
be examined later for structural abnormalities. The US examiner was blinded to participant
groupings.
Movement Assessment
Following the CAR trials, participants completed at least one familiarization trial
followed by three trials of a standardized jump-landing task. Participants were required to jump
forward a distance of half their height from a 30cm high box and land with each foot on a
separate non-conductive force plate (model 4060-NC; Bertec Corporation, Columbus, OH),
which sampled landing data at 1500 Hz. Immediately following landing, participants jumped for
maximal height in one fluid motion. Trials were repeated if the participants’ feet did not leave
the box at the same time, the participants did not immediately jump after landing, or if they
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jumped too far or too short. Each test was recorded by two video cameras, one in the sagittal
plane and one in the frontal plane. A single rater, blinded to group, evaluated the trials using the
Landing Error Scoring System (LESS), which is a valid and reliable clinical movement screening
tool. 20 The EMG system and electrode placement was not changed between CAR and jump
landing trials, but the system was synced with both force plates so that muscle activity could be
aligned in time during jump landing.
Data Reduction and Analyses
EMG data collected during isokinetic testing and jump landings were analyzed to
determine if differences in the average muscle activity during these tasks existed in participants
with PT. To do this, the raw EMG data were subsequently processed within the Noraxon
software (MR3, myoMuscle, Scottsdale Arizona, USA). Specifically, raw EMG signals were
band-pass filtered 6 to 1,000 Hz, rectified and then processed using a root-mean-square
algorithm with a 50-millisecond moving window. EMG collected during the isokinetic and jump
landing tasks were then normalized to the peak muscle activity that was recorded from either
task. Using this normalization technique, all normalized root-mean-square data were at or below
100% of muscle activity. 21 EMG data for the isokinetic testing were analyzed between the onset
of muscle contraction to 100msec prior to the burst. EMG during the landing task was then
analyzed during two phases of activity: pre-loading (100 milliseconds prior to ground contact)
and loading (ground contract to take-off) 22. Ground contact was defined as a force exceeding 10
Nm, while take off was defined as a force below 10 Nm 22.
Descriptive statistics are presented as means +/- SD. Statistical analyses were performed
using SPSS (Version 22). Independent t-tests were used to assess group differences between PT
and control participants for CAR, H:M ratio, LESS score, and average muscle amplitude during
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both CAR, and the pre-loading and loading phases of jump landing. Assumptions of equal
variance and normal distribution were ensured with no abnormalities. Descriptive statistics were
used to discuss differences in sonographic assessment. Significance was set a priori at an alpha
level of < 0.05 and 95% confidence interval (CI), reported as lower bound (LB) and upper bound
(UB), around the mean differences was calculated. Each dependent variable was considered
independent constructs thus Family Wise Error was not accounted in this analysis.

Chapter IV: Results

Demographics
No significant difference in age, gender, or mass existed between groups (see table 1,
p>0.05). The PT group was found to be significantly taller than the healthy group (see table 1,
p<0.05).

Table 1: Group Demographics (Mean ± SD)
Demographic
Age (years)
Gender
Height (cm)
Weight (kg)

Group
PT

n

Mean

95% CI: LB

95% CI: UB

6

20.83±0.98

Healthy

6

22.83±3.82

-5.59

1.59

PT

6

0.50±0.55

Healthy

6

0.50±0.55

-0.71

0.71

PT

6

177.80±6.81*

Healthy

6

170.20±4.18

0.32

14.87

PT

6

74.00±8.67

-7.21
6
69.67±9.27
*Indicates significance (p<0.05)
95% CI indicates difference between groups

15.87

Healthy
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VISA-P
All subjects in the PT group scored under an 80 on the VISA-P (62.67 ± 17.38), while all
healthy subjects scored at or above a 99 (99.83 ± .41). Both groups met the criteria defined by
the VISA-P for their respective groups.
US
Two of the six subjects in the PT group were classified as having PT through diagnostic
imaging, with one of the 2 being diagnosed with bilateral tendon involevment. The remaining
four subjects had no visible PT present in the affected limb (see Figure 1). All six of the healthy
subjects were shown to have no visual evidence of PT in either limb.

Figure 1. Demonstrates the tendons
from the involved limbs for the PT
group. A, C, D, and E refer to
participants with subjectively
reported PT, normal tendons
(Denoted by arrows). Tendons B
and F refer to diagnostic (objective)
PT as shown by their increased
width and areas of hypochoic
legions (Denoted by arrows).
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CAR
I observed a significant deficit in volitional muscle activation in the involved limb in
patients with patellar tendinopathy as compared to the healthy group (F = 10.279; p = .04; Cohen
d = 1.37; 95% CI: -6.60, -0.21, see table 2).
Table 2. Central Activation Ratio (Mean ± SD)
Limb

95% CI: LB

95% CI: UB

-6.60

-0.21

-3.26
6
97.98±1.12
*Indicates significance (p<0.05)
95% CI indicates difference between groups

1.25

Involved
Non-Involved

Group
PT

n

Mean

6

95.13±3.46*

Healthy

6

98.54±0.60

PT

6

96.97±2.21

Healthy

Muscle Activity
No significant differences were found between the PT and healthy groups for vastus
medialis or vastus lateralis activity during SIB, pre-loading, or loading (see tables 3-5, p>0.05).
Table 3. EMG: Percent maximal activation during CAR (Mean ± SD)
Limb: Muscle

Group
PT

n

Mean

6

15.67±19.89

Healthy

6

22.36±11.97

PT

6

23.32±15.14

Healthy

6

21.15±12.89

Non-Involved: Vastus
Lateralis

PT

6

20.43±20.78

Healthy

6

16.65±14.15

Non-Involved: Vastus
Medialis

PT

6

35.15±29.62

Involved: Vastus Lateralis
Involved: Vastus Medialis

Healthy

95% CI: LB

95% CI: UB

-27.85

14.37

-15.92

20.26

-19.09

26.66

-6.06

49.45

6
13.46±7.32
*Indicates significance (p<0.05)
95% CI indicates difference between groups
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Table 4. EMG: Percent maximal activation during pre-loading
(Mean ± SD)
Limb: Muscle
Involved: Vastus Lateralis
Involved: Vastus Medialis
Non-Involved: Vastus
Lateralis

Group
PT

n

Mean

6

7.93±5.34

Healthy

6

9.45±3.90

PT

6

9.06±3.29

Healthy

6

9.01±4.80

PT

6

8.56±4.24

Healthy

6

13.40±17.03

PT

6

95% CI:LB

95% CI: UB

-7.53

4.49

-5.25

5.34

-20.81

11.13

9.46±4.56
-8.03
6
10.21±6.57
*Indicates significance (p<0.05)
95% CI indicates difference between groups

Non-Involved: Vastus
Lateralis

Healthy

6.53

Table 5. EMG: Percent maximal activation during loading (Mean ± SD)
Limb: Muscle
Involved: Vastus Lateralis
Involved: Vastus Medialis
Non-Involved: Vastus
Lateralis

Group
PT

n

Mean

6

29.23±9.83

Healthy

6

42.37±14.05

PT

6

43.17±6.79

Healthy

6

34.93±16.61

PT

6

31.56±11.13

Healthy

6

26.23±11.13

PT

6

95% CI: LB

95% CI: UB

-28.51

2.22

-8.09

24.56

-8.99

19.64

38.00±15.33
-9.80
6 28.97±13.92
*Indicates significance (p<0.05)
95% CI indicates difference between groups

Non-Involved: Vastus
Lateralis

Healthy

27.87

Spinal Reflexive
No significant difference was found between the PT and healthy groups in H:M ratio (F =
2.665; p = 0.82; 95% CI: -0.20, 0.25, see table 6).

Table 6. H:M Ratio (Mean ± SD)
Limb
Involved
Non-Involved

Group
PT

n

Mean

6

0.22±0.23

95% CI: LB

95% CI: UB

Healthy

6

0.20±.09

-.20

.25

PT

6

0.30±.22

-.56
4
0.47±.32
*Indicates significance (p<0.05)
95% CI indicates difference between groups

.22

Healthy
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LESS Score
No significant difference was found between the PT and healthy groups in average LESS
score (F = .260; p = .66; 95% CI: -1.51, 2.29, see table 7).
Table 7. Average LESS Score (Mean ± SD)
LESS Score
Average

Group
PT

n

Mean

6

4.94±1.64

95% CI: LB

-1.51
6 4.56±1.29
*Indicates significance (p<0.05)
95% CI indicates difference between groups
Healthy

95% CI: UB
2.29

Sub-Group Analysis
To more accurately report CAR, H:M, muscle activity, and LESS the PT group was
divided into two sub-groups in addition to the PT group as a whole. First, a Subjective group,
diagnosed with PT based off subjective questionnaires, and second, an Objective group,
diagnosed with PT based off a combination of subjective reports and positive identification of
tendon abnormality via US, groups. The purpose of this division was to identify the differences
that appeared between subjects with and without tendon abnormality and to demonstrate varying
levels of severity within the PT group. All sub-group analyses were done descriptively due to
the small sample sizes.
Sub-Group CAR
The objective PT group demonstrated a lower CAR than both the subjective PT and
healthy groups (see table 8).
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Table 8. Central Activation Ratio with sub-groups (Mean
± SD)
Limb

Group
Objective PT

n

Mean

2

93.66±0.82

Involved

Subjective PT

4

99.00±0.62

Healthy

6

98.54±0.60

Objective PT

2

94.91±2.76

Subjective PT

4

98.00±1.15

Healthy

6

97.98±1.12

Non-Involved

Sub-Group EMG
The objective PT group exhibited lower vastus lateralis and medialis activation during
SIB, pre-loading, and loading trials in both the involved and non-involved limbs when compared
to both the subjective PT and healthy groups (see tables 9-11)

Table 9. EMG: Percent maximal activation during CAR
with sub-groups (Mean ± SD)
Limb: Muscle
Vastus Lateralis: Involved

Vastus Medialis: Involved

Vastus Lateralis:Non- Involved

Vastus Medialis: Non-Involved

Group
Objective PT

n

Mean

2

4.57±2.84

Subjective PT

4

21.14±23.11

Healthy

6

22.36±11.97

Objective PT

2

13.03±4.24

Subjective PT

4

28.47±16.43

Healthy

6

21.15±12.89

Objective PT

2

8.44±7.44

Subjective PT

4

26.42±23.62

Healthy

6

16.65±14.15

Objective PT

2

7.46±1.13

Subjective PT

4

49.00±26.36

Healthy

6

13.46±7.32
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Table 10. EMG: Percent maximal activation during preloading with sub-groups (Mean ± SD)
Limb: Muscle

Group
Objective PT

n
2

2.95±1.97

Vastus Lateralis: Involved

Subjective PT

4

10.43±4.61

Healthy

6

9.45±3.90

Objective PT

2

6.05±2.45

Subjective PT

4

10.56±2.64

Healthy

6

9.01±4.80

Objective PT

2

6.15±4.91

Subjective PT

4

9.77±4.02

Healthy

6

13.40±17.03

Objective PT

2

6.64±2.08

Subjective PT

4

10.88±5.03

Healthy

6

10.21±6.57

Vastus Medialis: Involved

Vastus Lateralis: Non-Involved

Vastus Lateralis: Non-Involved

Mean

Table 11. EMG: Percent maximal activation during
loading with sub-groups (Mean ± SD)
Limb: Muscle

Group
Objective PT

n

Mean

2

18.70±2.92

Vastus Lateralis: Involved

Subjective PT

4

34.49±5.75

Healthy

6

42.37±14.05

Objective PT

2

38.62±4.69

Subjective PT

4

45.44±6.98

Healthy

6

34.93±16.61

Objective PT

2

20.83±0.189

Subjective PT

4

36.92±9.56

Healthy

6

26.23±11.13

Objective PT

2

22.47±2.03

Subjective PT

4

45.77±12.21

Healthy

6

28.97±13.92

Vastus Medialis: Involved

Vastus Lateralis: Non-Involved

Vastus Lateralis: Non-Involved

37

Sub-Group Spinal Reflexive
The objective PT group was found to demonstrate a lower H:M ratio in both the involved
and non-involved limbs when compared to both the subjective PT and healthy groups (see table
11).

Table 12. H:M Ratio with sub-groups (Mean ± SD)
Limb

Group
Objective PT

n

Mean

2

0.07±0.05

Involved

Subjective PT

4

0.29±0.26

Healthy

6

0.20±0.09

Objective PT

2

0.14±0.04

Subjective PT

4

0.38±0.24

Healthy

4

0.47±0.32

Non-Involved

Sub-Group LESS Score
The objective PT group were found to higher LESS scores than the subjective PT and
healthy groups (see table 13).
Table 13. Average LESS Score with sub-groups
(Mean ± SD)
LESS Score

Group
Objective PT

n

Mean

2

6.67±0.47

Average

Subjective PT

4

4.08±1.20

Healthy

6

4.56±1.29

Chapter V: Discussion
This research study was the first to quantify AMI originating from peripheral sources in
the PT population. Prior research has evaluated cortically driven neuromuscular changes in
chronic PT cases 12 and deficits in strength exhibited by PT subjects 3 but neither previous study
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defined the amount of quadriceps inhibition present in the condition. The current study found
evidence of the presence of AMI resulting from peripheral mechanisms at the spinal cord level in
subjects with PT. Further, it was found that those subjects demonstrating objective PT, as
confirmed by US, also demonstrated alterations in muscle activity and movement control,
possibly resulting from the increased tendon abnormality.
Identifying Patellar Tendinopathy
The VISA-P is a means of determining the severity of PT based on subjective patient
reports of pain and dysfunction. From the results of this study, it is reasonable to suggest that the
VISA-P can also detect neuromuscular dysfunction since the PT group demonstrated neural
alterations, but further investigation would be needed. All subjects met their group’s VISA-P
inclusion criteria and were placed in the appropriate group. Although, there was variability
within the PT group as scores ranged from 30-79 respectively. This wide range demonstrated the
need for objective testing of tendon injury severity in addition to solely subjective reports of
pain.
As the abnormality and pain do not always occur together it was expected that there
would be discrepancies between subjective and objective reporting, which has been previously
demonstrated. 19,23 Only two of the six subjects in the PT group had tendon abnormalities upon
investigation by diagnostic US imaging (Fig. 1), while the remaining four PT participants did not
show any evidence of PT through imaging. This is important clinically because individually
both subjective and objective reporting measures can be used to detect PT, but combining both
measures may be the most cost effective and efficient method.
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Quantifying Arthogenic Muscle Inhibition
This study was the first to quantify AMI in PT patients using both CAR and H-Reflex.
Together these techniques allow for the identification of altered volitional muscle activation,
which is originating either from a decrease in motor neuron firing rate or the number of available
motor units, and an evaluation of the quality of afferent signaling from the muscle spindle
reaching the spinal cord. This is important because simply identifying the presence of AMI does
not describe the underlying source or mechanism. When looking at CAR, the PT group
demonstrated a decrease in volitional muscle activation as compared to the healthy group (Table
2). In particular, those individuals with tendon abnormalities on diagnostic imaging showed an
even larger decrease in volitional muscle activation when compared to both the remainder of the
PT group and healthy individuals (Table 8). These differences in CAR within the PT group may
have been caused by variations in the origin of AMI. Based on the data it appeared that the
subjective PT group may have been suffering from centrally driven AMI due to the decrease in
volitional muscle activation even with a lack of detectable peripheral mechanisms. Conversely,
the objective group may have been suffering from a combination of peripheral and central
mechanisms of AMI due to the chronic nature of their injuries. This thinking is derived from
previous literature showing chronic PT can cause cortical level changes 12,and my data that
demonstrated a decrease in H:M ratio. The observed decrease in volitional muscle activation, for
either group, did not reach levels seen in more serious injuries, like ACL rupture, which was
expected. PT does not exhibit similar levels of joint damage, swelling, or pain as are seen in
major ligament rupture. A second reason could be that even the two subjects with tendon
abnormality and a decreased CAR were still fully functional in sport.
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Unlike CAR, no difference in H:M appeared between the PT group and healthy
individuals (Table 6). Although, once the PT group was through US the objective PT group
demonstrated a lower H:M in both the involved and uninvolved limbs (Table 12). These data
suggest that the spinal cord is modifying afferent signaling from the periphery and could be a
result of dysfunction in the gamma loop, Renshaw cells or type 1a. Spinally induced AMI is not
caused by peripheral mechanisms, such as pain or effusion, which can be modulated by reducing
the amount of afferent signaling. In these peripheral models AMI can be reduced by simply
decreasing the amount of joint effusion or by reducing the amount of pain felt. This could be
why there was a difference between the two PT sub-groups in regards to H:M. The objective
group was likely suffering from peripherally driven AMI due to altered afferent feedback
resulting from tendon abnormality, while in both sub-groups centrally driven AMI resulting from
their chronic PT was likely caused a reduction in CAR as compared to the healthy group.
Functional Impact
As was previously reported, the results of this study show that PT can lead to AMI that is
likely originating from peripheral and central mechanisms, but neither CAR nor H-Reflex is a
measure of functionality during physical activity. It is important to understand how AMI in the
PT population translates into alterations in muscular activity and neuromuscular control during
functional activities.
Neuromuscular control during functional activities, such as a jump landing, is important
to evaluate due to its association with injury risk. 24 Previous work has linked AMI to functional
deficits in neuromuscular control that may explain the elevated risk of subsequent injury in
individuals after knee joint injury, but this work has been largely isolated to patients after ACL
injury. Palmeiri-Smith et al 25 found that patients with AMI generally demonstrate altered
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kinematics, but this research has not been thoroughly reproduced in the PT population. This is
one of the first studies to score jump landings in the PT population. While there were no
statistically significant differences between groups in LESS scores (Table 7) the objective PT
group demonstrated higher LESS scores than either other group (Table 13). Furthermore, the
mean scores for the objective PT group were above six, which has been shown to be predictive
of ACL injury in a youth population 26 and may suggest greater neuromuscular compromise in
these individuals. These findings support the critical need for clinicians to evaluate movement
control in patients recovering from knee joint injuries.
One possibility for the objective PT group’s increased scores was altered muscular
activity prior to and during landing. The objective PT group had generalized decreased activity
in the vastus medialis and lateralis that was not seen in the either the subjective or healthy
control groups and a lower percent max activation during the loading phase of jump landing in
the vastus lateralis. Conversely, the PT group demonstrated activation that was greater than or
equal to healthy individuals in all other trials (Table 5), but these data are not meant to suggest
that individuals with PT demonstrate normal levels of quadriceps activation. Once the PT group
was separated into subgroups it became apparent that those with diagnostically identified tendon
abnormality demonstrated decreased muscle activation during the SIB trials (Table 9) and the
pre-loading (Table 10) and loading phases (Table 11) of jump landing for both the vastus
lateralis and medialis muscle groups. This suggests that the objective PT group might have been
compensating with higher activation in a different muscle group that was not quantified in this
study through the use of EMG, or the group had an overall decrease in quadriceps muscle
activation, even on muscles not analyzed. The latter is supported through the objective PT
group’s decrease in CAR and increased LESS score. This could be evidence that AMI
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originating from central mechanisms can have an effect on muscular activity that is significant
enough to alter landing kinematics. Further investigation is warranted into the source of this
decreased activity and whether PT induced AMI is associated with injury risk. Clinically,
landing mechanics may be an area of observation that is added to PT evaluations.
Limitations
Overall, the limitations of this study were disparity between levels of dysfunction in the
PT group and its small sample size. One possibility that could explain why not all subjects
demonstrated neuromuscular dysfunction could be due to the disparities in the origin of the PT.
Peripheral mechanisms were shown to be affected in the two objective PT subjects through their
decreased H:M. Other subjects were not as acutely injured, which may explain why they did not
have alterations in H-Reflex outcomes. For these subjects cortical measures may have been
more appropriate to assess neuromuscular alterations. Cortical alterations have been
demonstrated in various ACL injury models 27,28 and previous literature suggests that chronic PT
can cause changes in cortical pathways, which caused neuromuscular dysfunction. 12 Further,
research into long term injury outcomes in subjects with previous ACL injury has shown that
these cortical alterations can evolve over time as a response to injury. 9 A larger sample of more
severely injured participants would be needed to accurately assess the amount of dysfunction
potentially caused by PT.
Future Direction
Future research needs to evaluate the effects of PT on neuromuscular function in a larger
sample consisting of acute and chronic PT of varying injury level. Further, this research should
aim to evaluate both peripheral and cortical pathways over time to see how the course of the
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injury may cause changes in neuromuscular outcomes. Finally, a protocol that includes a
treatment program would be necessary to observe how both peripheral and cortical pathways
evolve as tendon health improves. This rehabilitation plan should include ways to treat the
various underlying causes of AMI present in PT cases.
Conclusions
PT can lead to neuromuscular dysfunction in the quadriceps during varying levels of
activity. Individuals with PT exhibit quadriceps AMI that seems to partially stem from
peripheral inhibition at the spinal cord level. These individuals with objectively quantified PT
also demonstrate lower muscle activity during voluntary isometric contractions and the phases of
jump landing, which may be the source of their increased LESS scores. The topic of quadriceps
AMI caused by PT is novel and future research is needed to account for the small sample size
and relatively healthy PT population. An investigation into PT detrimental enough to cause a
cessation of athletic participation is needed to determine to what extent PT can influence
neuromuscular dysfunction and the origin of AMI in this population. Clinically, this research
presents data that subjects with PT could present with AMI of varying levels corresponding with
the amount of tendon abnormality. Rehabilitation practices should focus on not only the tendon
itself but also the quadriceps musculature, which are commonly used to combat AMI seen after
ligamentous injury. 7,29-31
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